SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Trickle Portfolio
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: tuck who wrote (826)9/17/2001 9:21:42 AM
From: tuck  Read Replies (1) of 1784
 
>>SAN DIEGO, Sept 17 (Reuters) - Biotechnology company Invitrogen Corp. (NasdaqNM:IVGN - news) said on Monday its board has authorized the repurchase of up to $150 million of its common stock.

Based on the stock's closing value of $70.37 on Sept. 10, the buy-back program represents up to 2.1 million shares, or four percent of Invitrogen's outstanding and issued shares.<<

snip

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News